MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
HTBX - Heat Biologics Inc
$8.41
-0.05(-0.59%)2:38:21 PM 2/25/2021
Heat Biologics Inc. is a US biotechnology company focused on the field of immunotherapy. This company's technology platform is called ImPACT, short for Immune Pan-Antigen Cytotoxic Therapy. The lead product HS-110 is in Phase II clinical trials and is being tested in NSCLC. It is based in Morrisville, North Carolina. ImPACT is a proposed technology platform based on live, genetically-modified, irradiated human cells which secrete a broad spectrum of cancer-associated antigens as well as an immune adjuvant called gp96. Potential advantages of this product are use as an 'allogeneic', that is, 'off-the-shelf' immunotherapy, and its applicability to a wide range of cancers. It is in phase II trials.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Stock news

    02/16/2021HTBX
    HTBX: HS-110 Phase 2 Interim Data

    By John Vandermosten, CFA NASDAQ:HTBX READ THE PREVIOUS HTBX RESEARCH REPORT HS-110 Interim Data Heat Biologics, Inc. (NASDAQ:HTBX) announced positive interim survival data for its Phase II trial of HS-110 (viagenpumatucel-L), a cell-based therapy, in combination with leading checkpoint blockade inhibitors (CBIs). The trial was not a comparator trial; however, similarities in design with past

    02/12/2021HTBX
    Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference

    DURHAM, NC / ACCESSWIRE / February 12, 2021 / Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product .

    02/10/2021HTBX
    Is Heat Biologics Stock a Buy Right Now? Analyst Weighs In

    Tuesday was a good day for investors of Heat Biologics (HTBX). Shares blasted off by 50%, after the biotech company announced positive interim data for its lung cancer treatment. Specifically, in the Phase 2 trial of HS-110, in combination with Bristol-Myers Squibb's OPDIVO (nivolumab) in advanced non-small cell lung cancer (NSCLC), there was a significant improvement to survival rates when the two treatments were put to work together. HS-110 is an allogeneic cell-based therapy intended to stren...

    02/10/2021HTBX
    Heat Biologics Stock Notches Scorching RS Rating

    On Wednesday, Heat Biologics got a positive adjustment to its Relative Strength (RS) Rating, from 89 to 96. The high RS Rating makes Heat Biologics stock one for your market rally watchlist. As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.

    02/9/2021HTBX
    Heat Biologics Catapults After Drug Regimen Boosts Lung-Cancer Survival

    Heat Biologics said Tuesday adding its experimental drug to Bristol Myers Squibb's Opdivo helped more lung-cancer patients survive. In response, HTBX stock catapulted.

    02/9/2021HTBX
    Heat Biologics Pops 77% On ‘Positive’ Lung Cancer Therapy Trial Data

    Heat Biologics shares spiked 77% as the biopharma company reported positive interim data from the Phase 2 trial of its lung cancer treatment. The Phase 2 trial tested Heat’s (HTBX) HS-110 in combination with Bristol Myers Squibb’s opdivo (nivolumab) as a therapy for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). HS-110 is Heat’s “off-the-shelf” cell-based therapy tailored to activate a patient’s immune system and induce a robust response against tumor cells. Heat Bio...

    02/9/2021HTBX
    Heat Biologics stock more than doubles after 'positive' trial data of its lung cancer treatment

    Shares of Heat Biologics Inc. more than doubled in very active trading Tuesday, after the biopharmaceutical company focused on modulating the immune system reported "positive" interim data from a Phase 2 trial of its lung cancer treatment. The stock soared 115% toward a seven-month high ahead of the open on volume of 15.1 million shares, which compares with the full-day average of 1.4 million shares over the past 30 days. The company said a trial of its HS-110, in combination with Britol-Myers S...

    02/9/2021HTBX
    Heat Biologics Cell Therapy Shows Survival Benefit In Mid-Stage Lung Cancer Study, Shares Rally

    Heat Biologics Inc (NASDAQ: HTBX) soars in premarket on the heels of encouraging interim data from the Phase 2 trial evaluating HS-110, in combination with Bristol-Myers Squibb's (NYSE: BMY) Opdivo (nivolumab) in advanced non-small-cell lung cancer (NSCLC). Median progression-free survival (PFS) of 1.8 months and median overall survival (OS) of 24.6 months was observed in checkpoint inhibitor naïve patients with advanced NSCLC (cohort A, N = 47). The one-year survival rate of Cohort A is 61.7%. ...

    02/9/2021HTBX
    Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

    6 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients who received HS-110 in combination with nivolumabDURHAM, NC / ACCESSWIRE / February 9, 2021 / Heat Biologics, Inc. ("Heat")(NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today reported positive interim data of the Company's fully-enrolled P...

    02/9/2021HTBX
    Heat Biologics Jumps on Progress With Lung-Cancer Drug

    Heat Biologics shares more than doubled after the biopharma reported progress in a trial of a lung-cancer-treatment candidate.